Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis
Clicks: 340
ID: 115341
2015
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
84.9
/100
339 views
267 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Vedolizumab is superior to placebo as induction and maintenance therapy for ulcerative colitis. Future studies are needed to define long-term efficacy and safety of this agent.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (26 words).
Try re-searching for a better abstract.
| Reference Key |
mh2015inflammatoryvedolizumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mosli MH;MacDonald JK;Bickston SJ;Behm BW;Tsoulis DJ;Cheng J;Khanna R;Feagan BG;; |
| Journal | inflammatory bowel diseases |
| Year | 2015 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
systematic review
meta-analysis
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
humans
pubmed abstract
nih
national institutes of health
national library of medicine
prognosis
research support
non-u.s. gov't
Remission Induction
Antibodies
Monoclonal
Brian G Feagan
Humanized / therapeutic use*
Colitis
Ulcerative / drug therapy*
Gastrointestinal Agents / therapeutic use*
induction chemotherapy
maintenance chemotherapy
pmid:25844963
doi:10.1097/mib.0000000000000396
mahmoud h mosli
john k macdonald
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.